Eli Silvert
Overview
Explore the profile of Eli Silvert including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
12
Citations
161
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Sandahl T, Soefje S, Fonseca R, Ailawadhi S, Parrondo R, Lin D, et al.
JCO Oncol Pract
. 2024 Dec;
:OP2400489.
PMID: 39705632
Purpose: Teclistamab is initiated with a step-up dosing (SUD) schedule to mitigate the risk of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). Early teclistamab users commonly...
2.
Matson R, Comba I, Silvert E, Niesen M, Murugadoss K, Patwardhan D, et al.
NPJ Syst Biol Appl
. 2024 Nov;
10(1):138.
PMID: 39604453
Understanding which viral variants evade neutralization is crucial for improving antibody-based treatments, especially with rapidly evolving viruses like SARS-CoV-2. Yet, conventional assays are labor intensive and cannot capture the full...
3.
Barman H, Venkateswaran S, Santo A, Yoo U, Silvert E, Rao K, et al.
JCO Clin Cancer Inform
. 2024 Apr;
8:e2300151.
PMID: 38687915
Purpose: Immune checkpoint inhibitors (ICIs) have revolutionized cancer treatment, yet their use is associated with immune-related adverse events (irAEs). Estimating the prevalence and patient impact of these irAEs in the...
4.
Barman H, Sikirica V, Carlson K, Silvert E, Carlson K, Boyer S, et al.
Mol Genet Metab
. 2023 Sep;
140(3):107695.
PMID: 37708666
Background: Propionic acidemia (PA) is a rare autosomal recessive organic acidemia that classically presents within the first days of life with a metabolic crisis or via newborn screening and is...
5.
Silvert E, Hester L, Ramudu E, Pawlowski C, Kranenburg B, Buadi F, et al.
Am J Hematol
. 2023 Jul;
98(9):E255-E258.
PMID: 37403432
No abstract available.
6.
Venkatakrishnan A, Anand P, Lenehan P, Ghosh P, Suratekar R, Silvert E, et al.
Sci Rep
. 2023 Jan;
13(1):257.
PMID: 36604461
The emergence of highly transmissible SARS-CoV-2 variants and vaccine breakthrough infections globally mandated the characterization of the immuno-evasive features of SARS-CoV-2. Here, we systematically analyzed 2.13 million SARS-CoV-2 genomes from...
7.
Pawlowski C, Silvert E, OHoro J, Lenehan P, Challener D, Gnass E, et al.
PNAS Nexus
. 2022 Jul;
1(3):pgac071.
PMID: 35860600
Case reports of patients infected with COVID-19 and influenza virus ("flurona") have raised questions around the prevalence and severity of coinfection. Using data from , and , we analyzed trends...
8.
Niesen M, Pawlowski C, OHoro J, Challener D, Silvert E, Donadio G, et al.
JAMA Netw Open
. 2022 Apr;
5(4):e227038.
PMID: 35420661
Importance: Recent reports on waning of COVID-19 vaccine-induced immunity have led to the approval and rollout of additional doses and booster vaccinations. Individuals at increased risk of SARS-CoV-2 infection are...
9.
Puranik A, Lenehan P, Silvert E, Niesen M, Corchado-Garcia J, OHoro J, et al.
Med
. 2021 Dec;
3(1):28-41.e8.
PMID: 34927113
Background: mRNA coronavirus disease 2019 (COVID-19) vaccines are safe and effective, but increasing reports of breakthrough infections highlight the need to vigilantly monitor and compare the effectiveness of these vaccines....
10.
Puranik A, Lenehan P, Silvert E, Niesen M, Corchado-Garcia J, OHoro J, et al.
medRxiv
. 2021 Aug;
PMID: 34401884
Although clinical trials and real-world studies have affirmed the effectiveness and safety of the FDA-authorized COVID-19 vaccines, reports of breakthrough infections and persistent emergence of new variants highlight the need...